Record-Setting Pace for New Drug Approvals in 2018

Record-Setting Pace for New Drug Approvals in 2018

Εγκρίθηκε νέα θεραπεία για την ημικρανία από την Eli Lilly

Εγκρίθηκε νέα θεραπεία για την ημικρανία

Aimovig launch bolsters hopes for blockbuster sales

Dive Brief: Strong initial demand for Amgen and Novartis' new preventive migraine therapy Aimovig has reinforced expectations of blockbuster sales — for one analyst at least. Since Aimovig's approval in May, total weekly prescriptions for the anti-CGRP drug have climbed to nearly 10,000, with more than 3,000 patients beginning treatment by the 10th week of … Συνεχίστε να διαβάζετε Aimovig launch bolsters hopes for blockbuster sales.

Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?

Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that by handing out a lot of the product for free. But are they having trouble switching those patients to full-paying customers, courtesy of their insurers, … Συνεχίστε να διαβάζετε Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?.

Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk

What Did Ian Read Learn From Trump? Pfizer Inc. CEO Ian Read may have as much insight as anyone in the pharma world into US President Donald Trump's thinking on drug pricing and potential policy steps, after talking to the president on the phone and visiting him at the White House in July. You can bet … Συνεχίστε να διαβάζετε Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk.

Novartis study validates need for better migraine treatment, as Novartis-Amgen drug hits market

  While Novartis and Amgen work to keep up with pent-up demand for their newly launched migraine treatment Aimovig, a new study backed by both pharma companies looks at real-world needs of migraine patients. The first data released from the “My Migraine Voice” survey, initiated and funded by Novartis and the European Migraine and Headache Alliance and … Συνεχίστε να διαβάζετε Novartis study validates need for better migraine treatment, as Novartis-Amgen drug hits market.